JP Morgan Chase’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.09M | Sell |
31,553
-75,464
| -71% | -$3.91M | ﹤0.01% | 4142 |
|
|
2026
Q1 | $4.89M | Buy |
107,017
+58,620
| +121% | +$2.6M | ﹤0.01% | 3323 |
|
|
2025
Q4 | $2M | Sell |
48,397
-144,059
| -75% | -$5.78M | ﹤0.01% | 4071 |
|
|
2025
Q3 | $7.47M | Buy |
192,456
+57,174
| +42% | +$1.86M | ﹤0.01% | 2983 |
|
|
2025
Q2 | $3.74M | Buy |
135,282
+18,870
| +16% | +$480K | ﹤0.01% | 3414 |
|
|
2025
Q1 | $2.59M | Sell |
116,412
-361,388
| -76% | -$7.44M | ﹤0.01% | 3679 |
|
|
2024
Q4 | $9.45M | Buy |
477,800
+277,827
| +139% | +$6.34M | ﹤0.01% | 2743 |
|
|
2024
Q3 | $5M | Buy |
+199,973
| New | +$4.87M | ﹤0.01% | 3218 |
|
|
2024
Q2 | – | Sell |
-22,185
| Closed | -$438K | – | 7578 |
|
|
2024
Q1 | $438K | Sell |
22,185
-23,785
| -52% | -$465K | ﹤0.01% | 4876 |
|
|
2023
Q4 | $806K | Buy |
45,970
+17,671
| +62% | +$290K | ﹤0.01% | 4483 |
|
|
2023
Q3 | $492K | Buy |
28,299
+2,679
| +10% | +$45.1K | ﹤0.01% | 4491 |
|
|
2023
Q2 | $361K | Buy |
25,620
+59
| +0.2% | +$790 | ﹤0.01% | 4691 |
|
|
2023
Q1 | $275K | Buy |
25,561
+5,736
| +29% | +$75.6K | ﹤0.01% | 4862 |
|
|
2022
Q4 | $297K | Buy |
19,825
+537
| +3% | +$7.82K | ﹤0.01% | 4829 |
|
|
2022
Q3 | $248K | Buy |
19,288
+1,115
| +6% | +$12.7K | ﹤0.01% | 4848 |
|
|
2022
Q2 | $175K | Buy |
18,173
+348
| +2% | +$3.25K | ﹤0.01% | 5146 |
|
|
2022
Q1 | $177K | Buy |
17,825
+3,431
| +24% | +$36.4K | ﹤0.01% | 5252 |
|
|
2021
Q4 | $169K | Buy |
14,394
+1,227
| +9% | +$15.1K | ﹤0.01% | 5443 |
|
|
2021
Q3 | $149K | Buy |
13,167
+411
| +3% | +$5.35K | ﹤0.01% | 5372 |
|
|
2021
Q2 | $178K | Buy |
12,756
+2,683
| +27% | +$40.8K | ﹤0.01% | 5302 |
|
|
2021
Q1 | $187K | Sell |
10,073
-1,812
| -15% | -$37.1K | ﹤0.01% | 5178 |
|
|
2020
Q4 | $210K | Buy |
11,885
+1,920
| +19% | +$33.7K | ﹤0.01% | 4792 |
|
|
2020
Q3 | $155K | Buy |
9,965
+3,550
| +55% | +$66.6K | ﹤0.01% | 4486 |
|
|
2020
Q2 | $163K | Sell |
6,415
-2,480
| -28% | -$51.8K | ﹤0.01% | 4358 |
|
|
2020
Q1 | $137K | Buy |
8,895
+4,314
| +94% | +$67.5K | ﹤0.01% | 4417 |
|
|
2019
Q4 | $51K | Buy |
4,581
+7
| +0.2% | +$61 | ﹤0.01% | 5121 |
|
|
2019
Q3 | $39K | Buy |
4,574
+742
| +19% | +$8.2K | ﹤0.01% | 5255 |
|
|
2019
Q2 | $52K | Buy |
3,832
+952
| +33% | +$14.8K | ﹤0.01% | 5150 |
|
|
2019
Q1 | $52K | Buy |
2,880
+1,222
| +74% | +$23.6K | ﹤0.01% | 5114 |
|
|
2018
Q4 | $47K | Buy |
1,658
+155
| +10% | +$3.23K | ﹤0.01% | 5103 |
|
|
2018
Q3 | $38K | Buy |
+1,503
| New | +$29.2K | ﹤0.01% | 5284 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
JP Morgan Chase's KNSA Position: Q2 2026 in Review
JP Morgan Chase reduced its Kiniksa Pharmaceuticals (KNSA) stake by 71% in Q2 2026, selling an estimated $3.91M and leaving 31,553 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #4142.
JP Morgan Chase first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $9.45M in Q4 2024. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- JP Morgan Chase held 31,553 shares of Kiniksa Pharmaceuticals worth $2.09M as of Q2 2026.
- JP Morgan Chase sold 75,464 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.91M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4142 holding.
- JP Morgan Chase first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
- JP Morgan Chase's Kiniksa Pharmaceuticals position peaked at $9.45M in Q4 2024.
- 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.